← Human Trials & Peer-Reviewed Studies
Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society.
Plain-language guide to PMID 10065662 (1999): double-blind randomized controlled trial of Therapeutic nicotine (patch, non-peptide) in 1,877 subjects.
Key Facts
- PMID
- 10065662
- Journal
- The European respiratory journal
- Year
- 1999
- Study type
- Randomized Controlled Trial
- Authors
- Tønnesen P et al. (8 authors)
- DOI
- 10.1034/j.1399-3003.1999.13b04.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.
The Collaborative European Anti-Smoking Evaluation (CEASE) was a European multicentre, randomized, double-blind placebo controlled smoking cessation study.
Thirty-six chest clinics enrolled a total of 3,575 smokers.
Who Took Part
The study group was 1,877 subjects.
The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and multicenter.
Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.
Neither the subjects nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.
More than one site took part, so the subjects came from several places.
What Was Measured
The Collaborative European Anti-Smoking Evaluation (CEASE) was a European multicentre, randomized, double-blind placebo controlled smoking cessation study.
PubMed files the paper under topics including Administration, Cutaneous, Nicotine, Patient Compliance and Smoking Cessation.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 1,877 subjects.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 1999 (The European respiratory journal), a journal based in England.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.